Molecular Engineering – How Semax Was Designed From a Hormone Fragment

That is, simplified to the maximum, the logic behind one of the most elegant lines of peptide chemistry: the engineering of hormone fragments. Take a biologically active and complex molecule, identify which portion of it does what you want, and create a synthetic version that preserves that specific function, without the unwanted effects of the original.

Semax is an almost textbook example of this approach. To understand what makes it interesting as an object of research, one must understand the engineering that created it. And that story begins not with Semax, but with one of the most multifunctional hormones in the human body: ACTH.

Science is not copying nature. It is editing it.

The starting point: what inside ACTH science wanted to extract

ACTH, the adrenocorticotropic hormone, is produced by the pituitary and has as its principal function stimulating the adrenal cortex to produce cortisol. When you are under stress, it is the HPA axis (hypothalamus-pituitary-adrenal) that activates this chain, and ACTH is the intermediating signal.

But ACTH is a long molecule, 39 amino acids. And researchers realized, over decades of study, that different fragments of this chain have distinct effects. The fragment between positions 4 and 10, called ACTH(4-10), demonstrated neurotrophic and nootropic properties in animal models. The critical detail: without the adrenocorticotropic activity. That is, without stimulating the adrenal cortex and without altering cortisol.

The interesting portion had been identified. Now, the challenge was to turn it into something usable as an object of research.

Why do hormone fragments matter for research? Much of what modern biochemistry investigates is not complete hormones, but synthetic fragments or analogs. The reason is practical: complete molecules frequently have multiple biological activities simultaneously, which makes it hard to isolate and study a specific effect. Fragments allow the researcher, in theory, to study one function at a time.

The problem that needed solving: stability

Peptides are structurally fragile. The human body is full of enzymes whose function is to degrade peptide chains, the so-called peptidases and proteases. A hormone fragment loose in a biological environment has a very short half-life: it is rapidly identified and disassembled.

ACTH(4-10) was no different. As an object of research, it presented an evident practical problem: it did not last long enough for its effects to be adequately studied. It was necessary to modify the molecule to increase its resistance to degradation, without destroying the activity that had awakened interest.

It was here that the ingenuity of molecular design came in.

A peptide that does not survive long enough to be studied is like a hypothesis that dissolves before it can be tested.

The solution: add three amino acids on the right end

The modification the researchers at the Russian Academy of Sciences introduced was elegant in its simplicity: the addition of a tripeptide, Pro-Gly-Pro (PGP), at the C-terminal end of the molecule. Three more amino acids. A surgical modification.

The effect was significant: PGP conferred on the resulting compound greater resistance to enzymatic degradation compared with the original ACTH(4-10) fragment. The molecule became biologically more stable, which makes it more tractable as an object of research. And the original neurotrophic activity was preserved, and potentially amplified.

The result was Semax: seven amino acids in total (the addition of PGP to the six-residue ACTH(4-10) fragment, with methionine added at the N-terminal position), synthesized as a pure peptide, without adrenocorticotropic hormonal activity.

The design in three steps

Why this design matters for neuroscience research

A molecule that modulates the central nervous system without activating the HPA axis is something researchers pay attention to. A large part of the compounds that affect cognitive function or neuroprotection come accompanied by impacts on cortisol, on interconnected hormonal systems, on cascades of side effects that complicate the interpretation of the data. Semax, at least in terms of what has been published, appears to operate more surgically.

The studies point to a primary mechanism centered on the BDNF/TrkB axis in the hippocampus, with effects measured on BDNF expression, on TrkB receptor activation, and on signaling cascades associated with synaptic plasticity. A small molecule, synthetically defined, with a relatively circumscribed pharmacological signature. That is what researchers need to build studies with good experimental resolution.

What makes an RUO peptide interesting as an object of research? High-purity synthetic RUO peptides allow researchers to work with molecules of controlled composition, verified per lot. This is essential for experimental reproducibility: knowing exactly what is being administered, at what concentration, with what degree of purity. The Semax supplied by Axion follows the standard of >98% purity verified by HPLC and mass spectrometry.

Molecular design as a language of research

Semax is, in a sense, a demonstration of how modern biochemistry thinks. It is not nature copied, it is nature edited. Take a fragment that exists in endogenous ACTH, remove what does not matter, add what solves the practical stability problem, verify that the activity of interest was preserved.

The result is a molecule that science has investigated for decades in multiple contexts, neuroprotection, synaptic plasticity, neurotrophic modulation, and that continues, in 2026, generating new data and questions. For a heptapeptide of surgical design created in the 1980s, that is not a small thing.

The conversation about what Semax can or cannot do in humans is still open, and science is honest about that. But the conversation about the elegance of the molecule itself? That one is already well resolved.